Table 1.
Efficacy of Prenatal Xenogeneic EGFP+-ASC Transplantation in the Rabbit
| |
|
|
|
EGFP+-ASC Biodistributionb |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gestational Period | Time of analysis after in utero intervention (weeks) | Delivery route (N)a | Provirus-positive animals | Heart | Liver | Kidney | Lung | Trachea | Esophagus | Gonads | Placenta |
| E17 | 8 | IA (5) | 3/5 (60%) | 0/5 (0%) | 1/5 (20%) | 1/5 (20%) | 0/5 (0%) | 2/5 (40%) | 1/5 (20%) | 0/5 (0%) | 0/5 (0%) |
| 16 | IA (9) | 6/9 (66.7%) | 0/9 (0%) | 0/9 (0%) | 1/9 (11.1%) | 5/9 (55.6%) | 1/9 (11.1%) | 0/9 (0%) | 0/9 (0%) | 2/9 (22.2%) | |
a
IA, intraamniotic. (N), number of EGFP+-ASC-treated fetuses.
b
The presence of proviral DNA in the different tissues from the in utero-treated fetuses was analyzed after genomic DNA extraction and polymerase chain reaction amplification using EGFP-specific primers. For each tissue, frequencies are displayed as number of provirus-positive animals/total number of EGFP+-ASC-treated animals analyzed.
ASC, adipose tissue-derived mesenchymal stem cell; EGFP, enhanced green fluorescent protein.